Recursion PharmaceuticalsRXRX
About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Employees: 500
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
102% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 6 (+0) [Q3]
2% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 46
2% less funds holding
Funds holding: 268 [Q2] → 263 (-5) [Q3]
10% less capital invested
Capital invested by funds: $1.91B [Q2] → $1.73B (-$183M) [Q3]
17.34% less ownership
Funds ownership: 110.7% [Q2] → 93.35% (-17.34%) [Q3]
42% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $19.8M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Needham Gil Blum 18% 1-year accuracy 30 / 171 met price target | 38%upside $11 | Buy Reiterated | 6 Feb 2025 |
Keybanc Scott Schoenhaus 58% 1-year accuracy 21 / 36 met price target | 25%upside $10 | Overweight Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 9 articles about RXRX published over the past 30 days









